Under the High Patronage of  
Mr Emmanuel MACRON  
President of the French Republic

Tuesday 7 November

<table>
<thead>
<tr>
<th><strong>Plenary session I</strong></th>
<th><strong>16:00-18:45</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Amphitheatre Bordeaux</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Chairs:** Irene Norstedt (Belgium) and Yazdan Yazdanpanah (France)

**Opening ceremony**  
16:00-17:00
- Yazdan Yazdanpanah, ANRS Maladies Infectieuses Emergentes/Inserm and Chair of the Forum Host Country Committee (France)
- Iliana Ivanova, European Commissioner for Innovation, Research, Culture, Education and Youth  
  *(Video presentation)*
- Laurent Muschel, acting Director General, Health Emergency and Response Authority (HERA), European Commission
- Tedros Adhanom Ghebreyesus, Director General, World Health Organisation  
  *(Video presentation)*
- Maria da Graça Carvalho, Member of the European Parliament  
  *(Video presentation)*
- Matshidiso Rebecca Moeti, Regional Director, World Health Organisation Africa Regional Office
- Jean Kaseya, Director General, Africa Centres for Disease Control and Prevention (Africa CDC)

**Dr Pascoal Mocumbi keynote address**  
17:00-17:25
- Michel Kazatchkine, Senior Fellow, Global Health Center, the Graduate Institute for International Affairs and Development (Switzerland)

**Dr Pascoal Mocumbi Prize**  
17:25-17:45
- **Presenters:** Marcel Tanner (Switzerland) and Sonia Mocumbi (Mozambique)

**Welcome message**  
17:45-18:00
- Henning Gädeke, Chair of the EDCTP Association and Chair of the Governing Body of the Global Health EDCTP3 Joint Undertaking (Germany)
- Sylvie Retailleau, Minister of Higher Education and Research (France)

**Outstanding Female Scientist Prize**  
18:00-18:15
- **Presenter:** Sylvie Retailleau (France)

**Keynote address**  
EDCTP Anniversary Presentation: EDCTP 20 years and beyond – from strategy and numbers to sustainable impact  
18:15-18:45
- Michael Makanga, Executive Director, EDCTP Association (The Netherlands)

**Cultural performance**  
18:45-19:00

**Welcome cocktail reception**  
19:00-20:45
## Wednesday 8 November

### 1.1 Sponsored satellite session

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Event Description</th>
<th>Organiser(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td>341</td>
<td>The PANdemic Preparedness PlaTform for Health and Emerging Infections’ Response (PANTHER)</td>
<td>PANTHER (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Presentations:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>What could 80% ready tools look like?</td>
<td>Nathalie Strub Wourgaft, PANTHER (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Could regulators be better prepared?</td>
<td>Margareth Ndomondo-Sigonda, AUDA-NEPAD (Ethiopia)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Preparing for a new flu pandemic: yes we can</td>
<td>Bernards Ogutu, Kenya Medical Research Institute (KEMRI, Kenya)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Preparing for phase 2 clinical trials: the need for more Phase 1 units in Africa</td>
<td>Salim Abdulla, Ifakara Health Institute (IHI, Tanzania)</td>
</tr>
</tbody>
</table>

### 1.1 Workshop

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Event Description</th>
<th>Organiser(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td>342A</td>
<td>Global Health EDCTP3: Presenting the new programme and its opportunities for collaboration</td>
<td>Global Health EDCTP3 Joint Undertaking (Belgium)</td>
</tr>
</tbody>
</table>

### Plenary session II

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Description</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:05-10:00</td>
<td>Bordeaux</td>
<td>Lessons learnt from COVID-19 – and other infectious diseases – positioning Africa for excellence in global health in the post-COVID-19 era</td>
<td>Marcel Tanner (Switzerland)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Keynote address</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lessons learnt from COVID-19 – and other infectious diseases – positioning Africa for excellence in global health in the post-COVID-19 era</td>
<td>Salim Abdool Karim, Centre for the AIDS Program of Research in South Africa (CAPRISA, South Africa)</td>
</tr>
</tbody>
</table>

### EDCTP Outstanding Research Team Prize

<table>
<thead>
<tr>
<th>Time</th>
<th>Presenter</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45-10:00</td>
<td>Hannah Akuffo (Sweden)</td>
<td>EDCTP Outstanding Research Team Prize</td>
</tr>
</tbody>
</table>

### Break

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10:30</td>
<td>Break</td>
</tr>
</tbody>
</table>

### 1.1 Parallel session

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-12:30</td>
<td>341</td>
<td>Coinfections and comorbidities</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Chairs:</strong> Marleen Temmerman (Kenya) and Johanna Schaefer (The Netherlands)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>OA-092</strong> Clinically relevant enantiomer specific R- and S-praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir: Implications for HIV and schistosomiasis co-infection</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>OA-102</strong> Reactivation of oncogenic herpesviruses is associated with co-infections causing severe inflammatory presentations in HIV-infected patients from Gugulethu, South Africa</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>OA-223</strong> Myocardial structure and function assessed by cardiac magnetic resonance in adolescents with perinatal-acquired HIV infection taking antiretroviral therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>OA-317</strong> A multi-component integrated HIV/HTN care model improves hypertension screening and control in rural Uganda: A cluster randomized trial</td>
</tr>
</tbody>
</table>
| OA-359 | Latent tuberculosis infection among people with diabetes mellitus in Uganda and Tanzania  
Andrew Peter Kyazze, Makerere University (Uganda) |
| OA-901 | Comorbidities in children and adolescents growing up with HIV: the need to focus beyond viral suppression  
Rashida Ferrand, London School of Hygiene and Tropical Medicine (UK) and Biomedical Research and Training Institute (Zimbabwe) |

### 1.2 Parallel session

**Emerging infectious diseases & surveillance**

**Chairs:** Peter Smith (United Kingdom) and Pauline Beattie (The Netherlands)

| OA-195 | Spatial clustering, hotspot analysis and temporal distribution of the seventh Ebola Virus Disease outbreak in Uganda  
George Paasi, Mbale Clinical Research Institute (Uganda) |
| OA-235 | Antibody responses to endemic coronaviruses in South Africa  
Rubina Bunjun, University of Cape Town (South Africa) |
| OA-333 | Kinetics of antibody in Ebola survivors following specific anti-Ebola treatment in the Democratic Republic of the Congo  
Antoine Nkuba Ndaye, Institut National de Recherche pour le Développement (France) |
| OA-544 | T cell responses to SARS-CoV-2 infection and vaccination in people living with HIV  
Wendy Burgers, University of Cape Town (South Africa) |
| OA-652 | Safety and tolerability of favipiravir for the treatment of Lassa fever: a randomized controlled open label phase II clinical trial  
Mirjam Groger, Bernhard Nocht Institute for Tropical Medicine (BNITM, Germany) |
| OA-801 | Surveillance of respiratory viruses in Gabon during the COVID-19 pandemic  
Georgelin Nguema Ondo, Centre de Recherches Médicales de Lambaréné (CERMEL, Gabon) |

### 1.3 Parallel session

**Strengthening the ethics and regulatory framework**

**Chairs:** Michelle Singh (South Africa) and Nuraan Fakier (South Africa)

| OA-053 | Using technology to build a regulatory ecosystem across Africa to help streamline regulatory approval timelines, so doing, unlocking more investment into the continent  
Adriaan Kruger, NuvoteQ (South Africa) |
| OA-087 | Research ethics committees in Mozambique: operational and functional characteristics evaluated from a self-assessment tool in 2019  
Esperança Sevène, Eduardo Mondlane University (Mozambique) |
| OA-442 | Legislative, educational, training, institutional and social impact evaluation of the BERC-Luso project in the Portuguese-speaking African countries  
Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Portugal) |
| OA-510 | Contribution of the BREDSAFCA project to the sustainable evolution of research participants protection in Cameroon  
Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroon) |
| OA-713 | Achieving the ISO9001 certification: a milestone in quality management for the national research ethics committee: the case of the Senegalese National Research Ethics Committee  
Samba Cor Sarr, Health Research Authority (Senegal) |
| OA-721 | Leveraging digital platforms to support a sustainable national research information management system for research ethics and regulation in Uganda  
Maxwell Otim Onapa, Busitema University (Uganda) |

| Networking lunch | 12:30-14:00 |
| Meet the experts I | 12:30-13:30 |
| Poster presentations - A | 12:45-14:00 |
### 1.2 Workshop

**WHO's Clinical Trial Resolution: Better Evidence, a Stronger Ecosystem**

Organiser: Vasee Moorthy, Senior Advisor, WHO Science Division (Switzerland)

#### 1.1 Scientific symposia

**Ensuring that Children with HIV in Africa survive and thrive: Celebrating the CHAPAS 4 trial partnership**

Organiser: University College London (United Kingdom)

Chairs: Victor Musiime (Uganda) and Bwendo Nduna (Zambia)

Presentations:
- **Optimising metabolic and bone health in Children living with HIV**
  Mutsa Bwakura-Dangarembizi, University of Zimbabwe (Zimbabwe)
- **Pharmacokinetics of drugs for second-line antiretroviral therapy among children and adolescents living with HIV**
  Hylke Waalewijn, University of Cape Town (South Africa)
- **Capacity strengthening through ‘hub-and-spoke’ within-country mentoring of new research centres, and training early career researchers in Africa and Europe, leveraging on a clinical trial network**
  Veronica Mulenga, University of Zambia (Zambia)

#### 1.2 Scientific symposia

**Partnerships for implementation research to optimise the impact of Seasonal Malaria Chemoprevention in West and Central Africa: the OPT-SMC project**

Organiser: Université de Thiès (Senegal)

Chairs: Jean-Louis Ndiaye (Senegal) and Corinne Merle (Switzerland)

Presentations:
- **Regional partnerships for strengthening implementation research to improve access to SMC**
  Jean-Louis Ndiaye, Université de Thiès (Senegal)
- **Scaling-up of SMC in Nigeria: community perceptions and public engagement, a qualitative study in 5 States**
  Nnenna Ogbulafor, National Malaria Elimination Programme (Nigeria)
- **Barriers to SMC access in urban areas in Burkina Faso and strategies to improve uptake**
  Aissata Barry, Programme National de Lutte contre le Paludisme (Burkina Faso)
- **Scaling-up of SMC in Guinea: adapting strategies in hard-to-reach populations**
  Bienvenu Camara, Maferinyah Research Centre (Guinea)
- **Evaluating three strategies to improve adherence to SMC in Mali**
  Mady Cissoko/Aissata Kone, Programme National de Lutte contre le Paludisme (Mali)
- **Summary and forward look for the control of seasonal malaria**
  Fatimata Sall, Université de Thiès (Senegal)

#### 1.3 Scientific symposia

**A paradigm shift towards local and gender balanced leadership, promoting equitable partnerships and next generation African leaders, PAMAfrica-SINDOFO case studies**

Organiser: Centro de Investigação em Saúde de Manhiça (CISM, Mozambique)

Chairs: Rella Zoleko Manego (Gabon) and Innocent Valea (Burkina Faso)

Presentations:
- **Capacity building, shifting the paradigm of traditional North-South collaboration practice, fostering equitable partnerships and building an African leadership**
  Charles S Mgome, former Executive Director of EDCTP (Tanzania) *(Video presentation)*
### What is takes to enhance an equitable and sustainable research in Africa, a case study of an innovative clinical trial delivery
Ghyslain Mombo-Ngoma, Centre de Recherches Médicales de Lambaréné (CERMEL, Gabon)

### Career progression in clinical research for future leaders, addressing gender and opportunity challenges through advanced degree and practical training to enrich African clinical trial ecosystem
Dearie Okwu, PhD student, CERMEL (Gabon) and Jessica Dalsuco, PhD student, CISM (Mozambique)

<table>
<thead>
<tr>
<th>Break</th>
<th>15:30-16:00</th>
</tr>
</thead>
</table>

#### Plenary session III | 16:00-17:15 |
Chairs: Lara Pandya (The Netherlands) and Marleen Temmerman (Kenya)

**Ana Lúcia Cardoso Weinberg keynote address**

Preventing maternal deaths, care and prevention of severe complications of pregnancy and early life: The interaction between infectious and non-communicable diseases  
Claudia Hanson, Karolinska Institutet (Sweden)

| Panel: Preventing maternal deaths, care and prevention of severe complications of pregnancy and early life, addressing disparities in outcomes for women and babies from different population groups | 16:25-17:15 |
Moderator: Marleen Temmerman, Aga Khan University (Kenya)

Speakers:
- Barbara Kerstiëns, European Commission
- Esperança Sevone, Eduardo Mondlane University (Mozambique)
- Jean-Paul Dossou, Centre de Recherche en Reproduction Humaine et en Démographie (CERRHUD, Benin)
- Philippe Van de Perre, Université de Montpellier (France)

| Break | 17:15-17:45 |

#### Meet the Researchers of PALOP: health science research in the Portuguese speaking African countries | 17:45-18:45 Room 341 |

Presenters:
- Martin Essayan, Calouste Gulbenkian Foundation (Portugal) (Video presentation)
- HRH Infanta Cristina of Spain
- Eusebio Macete, Manhiça Health Research Centre (CISM, Mozambique)
- Angola: Claudia Videira, Centro de Investigação de Saúde de Angola
- Cabo Verde: Neidy Rodrigues, Universidade de Cabo Verde
- Guinea Bissau: Baltazar Cã, Instituto Nacional de Saúde Publica (INASA)
- Mozambique: Nilsa de Deus, Instituto Nacional De Saúde (INS)

#### Meet the Editors | 17:45-18:45 Room 342A |
Chairs: Michelle Helinski (The Netherlands) and Moses Bockarie (Sierra Leone)

Presenters:
- Marco De Ambrogi, Deputy Chief Editor of Lancet Infectious Diseases (United Kingdom)
- João Monteiro, Chief Editor, Nature Medicine (United States)
- David Ofori-Adjei, Editor-in-Chief, Ghana Medical Journal (Ghana) (*Virtual participation*)
Thursday, 9 November

### 2.1 Workshop

**EDCTP Knowledge Hub**
Organiser: The Global Health Network (United Kingdom)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td>Workshop</td>
</tr>
</tbody>
</table>

#### 2.1 Sponsored satellite session

**Mind the Gap: Perspectives on the pilot implementation of the first malaria vaccine**

Organiser: PATH (United States)
Chair: Evelyn Ansah (Ghana)

<table>
<thead>
<tr>
<th>Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Introduction</strong>                Professor Evelyn Ansah, Centre for Malaria Research, University of Health and Allied Sciences (Ghana)</td>
</tr>
<tr>
<td><strong>Background to the Pilot Implementation of the RTS,S Malaria Vaccine</strong>       Mary Hamel, World Health Organization</td>
</tr>
<tr>
<td><strong>Learning by Doing</strong>            Rose Jalang'o, National Vaccines and Immunizations Programme (Kenya)</td>
</tr>
<tr>
<td><strong>Nesting the Phase 4 in the Pilot Implementation</strong>                        Miloje Savic, Global Health Vaccines &amp; Adjuvants, GSK Vaccines (Belgium)</td>
</tr>
<tr>
<td><strong>When to Invest?</strong>               Jonathan Hutchin, MedAccess (United Kingdom)</td>
</tr>
<tr>
<td><strong>Concluding remarks</strong>            Evelyn Ansah, Centre for Malaria Research, University of Health and Allied Sciences (Ghana)</td>
</tr>
</tbody>
</table>

### Plenary session IV

Chair: Harleen Grewal (Norway) and Moses Bockarie (Sierra Leone) *(TBC)*

**Keynote address**

**Africa needs stronger institutions: what is making it happen?**
Abdoulaye Djimdé, University of Bamako (Mali)

**Audience Q&A**

**EDCTP Scientific Leadership Prize**
Presenter: Thomas Nyirenda (South Africa)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:05-10:00</td>
<td>Plenary session IV</td>
</tr>
</tbody>
</table>

#### Break

10:00-10:30

### 2.1 Parallel session

**Neglected infectious diseases: diagnosis, treatment and prevention**
Chairs: Michelle Helinski (The Netherlands) and Michael Ramharter (Germany)

<table>
<thead>
<tr>
<th>Code</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>OA-062</td>
<td>Improved molecular diagnosis of visceral leishmaniasis (VL) using the mini direct on blood PCR Nucleic Acid Lateral Flow Immunoassay (dbPCR-NALFIA) Henk Schallig, Academic Medical Center (Netherlands)</td>
</tr>
<tr>
<td>OA-196</td>
<td>Development of a CAA/CCA duplex test for improved diagnosis of human schistosomiasis Pytsje Hoekstra, Leiden University Medical Center (Netherlands)</td>
</tr>
<tr>
<td>OA-270</td>
<td>Skin diseases and their frequency patterns in skin camps in PEP4LEP implementing districts in Tanzania, preliminary results Nelly Mwageni, Catholic University of Health and Allied Sciences (Tanzania)</td>
</tr>
</tbody>
</table>
| OA-445 | A phase II/III multicenter randomized clinical trial evaluating the safety and efficacy of a single and three-day albendazole-ivermectin fixed-dose versus albendazole to treat soil-transmitted helminthiases  
Jose Muñoz, ISGLOBAL (Spain) |
| OA-504 | Towards an arsenic-free oral treatment for human African trypanosomiasis due to *T. b. rhodesiense*: a new tool for disease elimination  
Olaf Valverde Mordt, Drugs for Neglected Diseases initiative (DNDi, Switzerland) |
| OA-765 | Molecular diagnostic tests specificities and their contribution for HAT postelimination monitoring in Burkina Faso and Côte d’Ivoire  
Charlie Franck Alfred Compaoré, Institut de Recherche Pour Le Développement (Burkina Faso) |

### 2.2 Parallel session

**Advances in drug development in TB and HIV**

**Chairs:** Jean Marie Habarugira (Belgium) and Aleksandra Conversano (Belgium)

| OA-083 | Early bactericidal activity of meropenem, ertapenem, amoxicillin/clavulanate and optimized rifampicin in pulmonary tuberculosis  
Caryn Upton, TASK (South Africa) |
| OA-225 | Optimising second line anchor drug options for children with HIV in Africa: 96-week results of the CHAPAS-4 randomised trial  
Abbas Lugemwa, Joint Clinical Research Centre (Uganda) |
| OA-286 | Plasma concentrations of first line antituberculosis drugs in infants with HIV and severe pneumonia: a pharmacokinetic sub-study of the EMPIRICAL trial  
Chishala Chabala, University of Zambia, School of Medicine (Zambia) |
| OA-451 | Spirometry, diffusion capacity, absolute lung volumes and PET/CT findings upon completion of tuberculosis treatment – preliminary findings of StatinTB/ExtendTB trial  
Friedrich Thienemann, University of Cape Town (South Africa) |
| OA-770 | Treatment outcomes of low-level viremia among adults living with HIV on dolutegravir-based first line antiretroviral therapy in Botswana  
Ontlametse T Bareng, Botswana Harvard AIDS Institute (Botswana) |
| OA-739 | High-levels of HIV drug resistance persist in ART-experienced patients post-dolutegravir rollout in KwaZulu-Natal, South Africa  
Aabida Khan, Department of Virology, University of KwaZulu-Natal, Durban (South Africa) |

### 2.3 Parallel session

**Capacity strengthening**

**Chairs:** Thomas Nyirenda (South Africa) and Lydia Boudarene (Belgium)

| OA-252 | East and Southern African Consortium for Outbreak Epidemiology Training (ENTRANT)  
Emily Webb, London School of Hygiene & Tropical Medicine (LSHTM, United Kingdom) |
| OA-322 | Bridging the research gaps on AMR in sub-Saharan Africa – a One Health approach  
Rea Kobialka, Institute of Animal Hygiene and Veterinary Public Health, University of Leipzig (Germany) |
| OA-345 | The 1,000 global research studies challenge: developing nursing, midwifery and community health workers’ research leaders to transform global healthcare  
Trudie Lang, University of Oxford (United Kingdom) |
| OA-365 | Capacity building as a response to emerging and re-emerging infectious diseases in Africa  
Peter Olupot-Olupot, Mbane Clinical Research Institute / Busitema University (Uganda) (Video presentation) |
| OA-408 | Clinical trial capacity building from scratch: the WANECAM 2 experience in Niamey, Niger  
Abdoulaye Djimde, WANECAM 2 – University of Science, Techniques and Technologies of Bamako (Mali) |
| OA-686 | Advancing research on epidemic prone-pathogens: “Integrated Services for Infectious Disease Outbreak Research” (ISIDORe)  
Jonathan Ewbank, ERINHA (Belgium) |

**Networking lunch**

12:30-14:00
## Meet the experts II

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-13:30</td>
<td>Poster presentations – B</td>
</tr>
<tr>
<td>13:00-13:45</td>
<td><strong>2.2 Workshop</strong></td>
</tr>
<tr>
<td></td>
<td>Horizon Europe: Funding opportunities for your infectious disease</td>
</tr>
<tr>
<td></td>
<td>research projects and meet the network of European contact points</td>
</tr>
<tr>
<td></td>
<td>for health to help you</td>
</tr>
<tr>
<td></td>
<td>Organiser: Health-NCP-Net 3.0 (HNN 3.0)</td>
</tr>
<tr>
<td></td>
<td><strong>2.4 Parallel session</strong></td>
</tr>
<tr>
<td>14:00-16:00</td>
<td><strong>Advances in vaccines &amp; neutralising antibodies development</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Nicola Viebig (Germany) and Christine Stabell Benn (Denmark)</td>
</tr>
<tr>
<td>OA-240</td>
<td>Determining whether mass vaccination campaigns with fractional-dose</td>
</tr>
<tr>
<td></td>
<td>PCV10 (PNEUMOSIL) could accelerate group protection against</td>
</tr>
<tr>
<td></td>
<td>pneumococcal transmission in sub-Saharan Africa</td>
</tr>
<tr>
<td></td>
<td>Issaka Soumana, Epicentre (Niger)</td>
</tr>
<tr>
<td>OA-344</td>
<td>Clinical development in Burkina Faso of novel malaria vaccines based</td>
</tr>
<tr>
<td></td>
<td>on the Pfs48/45 antigen</td>
</tr>
<tr>
<td></td>
<td>Jordan Plieskatt, Statens Serum Institut (Denmark)</td>
</tr>
<tr>
<td>OA-490</td>
<td>Safety, reactogenicity and immunogenicity of MTBVAC in newborns in</td>
</tr>
<tr>
<td></td>
<td>a TB endemic area: a phase 2a randomized, double-blind, dose-defining</td>
</tr>
<tr>
<td></td>
<td>trial</td>
</tr>
<tr>
<td></td>
<td>Ingrid Murillo Jelsbak, Biofabri SLU (Spain)</td>
</tr>
<tr>
<td>OA-498</td>
<td>PedMaB1 clinical trial: Safety assessment of CAP256V2LS to prevent</td>
</tr>
<tr>
<td></td>
<td>breastfeeding HIV transmission in HIV-1 exposed uninfected neonates</td>
</tr>
<tr>
<td></td>
<td>Gabriella Scarlatti, IRCCS Ospedale San Raffaele (Italy)</td>
</tr>
<tr>
<td>OA-722</td>
<td>Assessment of naturally acquired humoral immunity against malaria</td>
</tr>
<tr>
<td></td>
<td>protecting against controlled human malaria infection (CHMI)</td>
</tr>
<tr>
<td></td>
<td>Nouhou Barry, University of Tübingen (Germany)</td>
</tr>
<tr>
<td>OA-779</td>
<td>Beneficial non-specific effects of oral polio vaccinations campaigns</td>
</tr>
<tr>
<td></td>
<td>– did one drop save more lives than anyone could have imagined?</td>
</tr>
<tr>
<td></td>
<td>Sebastian Nielsen, University of Southern Denmark (Denmark)</td>
</tr>
<tr>
<td>OA-272</td>
<td>Health system costs of decentralized TB diagnostic testing with Molbio</td>
</tr>
<tr>
<td></td>
<td>Truenat MTB/RIF vs. hub-and-spoke GeneXpert MTB/RIF in Mozambique and</td>
</tr>
<tr>
<td></td>
<td>Tanzania</td>
</tr>
<tr>
<td></td>
<td>Akash Malhotra, Johns Hopkins University (United States)</td>
</tr>
<tr>
<td>OA-208</td>
<td>Evaluating the impact of computer-assisted x-ray diagnosis and other</td>
</tr>
<tr>
<td></td>
<td>triage tools to optimise Xpert orientated community-based active case</td>
</tr>
<tr>
<td></td>
<td>finding for TB and COVID-19 (XACT-19)</td>
</tr>
<tr>
<td></td>
<td>Alex Scott, Centre for Lung Infection and Immunity, University of</td>
</tr>
<tr>
<td></td>
<td>Cape Town Lung Institute (South Africa)</td>
</tr>
<tr>
<td>OA-464</td>
<td>Clinical predictors of tuberculosis in children – a prospective study</td>
</tr>
<tr>
<td></td>
<td>in five low-middle income countries</td>
</tr>
<tr>
<td></td>
<td>Laura Olbrich, Ludwig-Maximilians-University (Germany)</td>
</tr>
<tr>
<td>OA-484</td>
<td>Improving rapid detection of 2nd line drug resistance in Mycobacterium</td>
</tr>
<tr>
<td></td>
<td>tuberculosis with Xpert MTB/XDR and MolBio 2nd line</td>
</tr>
<tr>
<td></td>
<td>Bouke De Jong, Institute of Tropical Medicine (Belgium)</td>
</tr>
<tr>
<td>OA-724</td>
<td>Interrogation of an multi drug resistant tuberculosis outbreak using</td>
</tr>
<tr>
<td></td>
<td>whole genome sequencing</td>
</tr>
<tr>
<td></td>
<td>Elizabeth Streicher, Stellenbosch University (South Africa)</td>
</tr>
</tbody>
</table>
2.6 Parallel session

Community engagement

<table>
<thead>
<tr>
<th>OA-097</th>
<th>Facilitators and barriers to infant HIV post-natal prophylaxis (PNP), a qualitative sub-study of the PROMISE-EPI trial in Lusaka, Zambia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Anaïs Mennecier, Université de Montpellier (France)</td>
</tr>
<tr>
<td>OA-271</td>
<td>Stakeholders’ perspectives and willingness on use of SMS reminders and mobile money incentives to reduce loss to follow-up among presumptive TB patients in Uganda</td>
</tr>
<tr>
<td></td>
<td>Esther Buregyeya, Makerere University School of Public Health (Uganda)</td>
</tr>
<tr>
<td>OA-506</td>
<td>Working towards better guidance for studies that involve African healthy volunteers in the context of the VoREthics initiative</td>
</tr>
<tr>
<td></td>
<td>Esperança Sevene, Eduardo Mondlane University (Mozambique)</td>
</tr>
<tr>
<td>OA-601</td>
<td>Acceptability of the future introduction of intermittent preventive treatment for malaria in infants in Massinga district, Mozambique</td>
</tr>
<tr>
<td></td>
<td>Neusa Torres, Manhiça Health Research Centre (CISM, Mozambique)</td>
</tr>
<tr>
<td>OA-667</td>
<td>HIV self-testing uptake and linkage to HIV care among male fisherfolk in two fishing communities in rural Uganda: early results from the PEST4MEN study</td>
</tr>
<tr>
<td></td>
<td>Joseph KB Matovu, Makerere University School of Public Health (Uganda)</td>
</tr>
<tr>
<td>OA-815</td>
<td>A community approach to re-thinking the principles of good randomized controlled trials: informative, respectful, collaborative, feasible and well-managed</td>
</tr>
<tr>
<td></td>
<td>Rachel Hallett, The Good Clinical Trials Collaborative (GCTC, United Kingdom)</td>
</tr>
</tbody>
</table>

Break 16:00-16:30

2.1 Scientific symposia

Making diagnostics accessible – beyond diagnostic platforms and assays

Organiser: Foundation for Innovative New Diagnostics (FIND, Switzerland)

Chairs: Katharina Kranzer (United Kingdom) and Alberto Garcia-Basteiro (Spain)

Presentations:

- **A diagnostic testing algorithm for inpatients living with HIV – the TB-CAPT EXULTANT trial**
  Marta Cossa, Manhiça Health Research Centre (Mozambique)

  Real life implementation of Molbio Truenat by the National TB Program in Kenya – what works and what does not work
  Immaculate Kathure, Ministry of Health (Kenya)

  Improving access to new TB diagnostic tools in Africa: bridging the research to national policy gap, to accelerate adoption and scale up
  Marguerite Massinga Loembe, African Society for Laboratory Medicine (ASLM, Ethiopia)

  Lessons learned from the XPEL-TB trial assessing the effectiveness and implementation of a streamlined strategy for delivery of Xpert Ultra testing
  Achilles Katamba, Makerere University (Uganda) (Video presentation)

  Implementation of the Xpert MTB/XDR diagnostic test into routine laboratory algorithms in South Africa; key strategies to overcome challenges
  Pedro da Silva, National Priority Programmes (NPP, South Africa)

  Implementation of the Molbio Truenat/MTB Assays at Primary Health Centers in Tanzania and Mozambique - the TB-CAPT CORE trial
  Celso Khosa, Instituto Nacional de Saúde (INS, Mozambique)

  Making diagnostics accessible – beyond diagnostic platforms and assays
  Panel discussion

2.2 Scientific symposia

Break 16:30-18:00

Room 342A
### From the bench to the field: contextual complexities in access and delivery of new health technologies in African health systems

| Organiser: | University of Health and Allied Sciences (Ghana) |
| Chairs: | Jürg Utzinger (Switzerland) |
| Presentations: | **African health research systems and Early-Stage Research and Development of innovative health technologies**  
Olumide Ogundahunsi, University of Medical Sciences (Nigeria) |
| | **Health system readiness and Implementation Research to support the access and delivery of new health technologies in Africa**  
Margaret Gyapong, University of Health and Allied Sciences (Ghana) |
| | **Capacity building in readiness for implementation and public health impact**  
Garry Aslanian, TDR the Special Programme for Research and Training in Tropical Diseases (Switzerland) |
| | **Regulatory Frameworks and Policies to support the access and delivery of new health technologies**  
Cecilia Oh, UNDP Access and Delivery Partnership (Thailand) |

### 2.3 Scientific symposia

**Working toward impactful clinical trials through collaborative research in sub-Saharan Africa: The example of the EDCTP NoEs**

| Organiser: | EDCTP Regional Networks of Excellence and The Global Health Network (United Kingdom) |
| Chairs: | Souleymane Mboup (Senegal), Francine Ntoumi (Congo) and Bernard Kikaire (Uganda) |
| Presentations: | **Strengthening the regulatory landscape for clinical research: capacity building of NRAs and ECs in Central Africa through EDCTP funding**  
Francine Ntoumi/Jolivet Mayela/Leonard Numfor/Gauthier Mesia, CANTAM (Congo/Cameroon) |
| | **More than 10 years of Coordinating a Capacity Building for ICH-GCH Research Program in Sub-Saharan Africa: Experiences from East Africa**  
Bernard Kikaire, EACCR (Uganda) |
| | **Trials of Excellence in Southern Africa: a collaborative effort of Southern African research institutes and universities involved in Clinical Trials**  
Rodrigues Matcheve, TESA III (Mozambique) |
| | **Contribution of WANETAM in the research Ecosystem in West Africa**  
Assan Jaye/Jean Pierre N’Guessan/Badou Gaye /Bai Lamin Dondeh, WANETAM (Senegal/Ivory Coast) |
| | **The New Ecosystem for health research and data science, why, for whom and when**  
Frank Kagoro/Elvis Temfack, TGHN (Tanzania/United Kingdom), Africa CDC (Ethiopia/Cameroon) |
| | **Empowering Girls and Women in Science Careers in Africa: Action by NoEs**  
NoEs |

### Global Health EDCTP3 networking dinner

<table>
<thead>
<tr>
<th></th>
<th>19:00</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Room 342B</td>
</tr>
</tbody>
</table>
Friday 10 November

3.1 Sponsored satellite session

08:00-09:00
Room 341

Nothing less than health for all: Essential elements for sustainable NTD control and elimination through medical innovation

Organiser: Drugs for Neglected Diseases initiative (DNDi, Switzerland)

Presentations:
- **Introduction and welcome**
  Luis Pizarro, DNDi (Switzerland)

- Innovative R&D and built capacity for the elimination of sleeping sickness
  Florent Mbo, HAT Platform/DNDi (Democratic Republic of Congo)

- Visceral leishmaniasis: on the brink of game-changing treatment options
  Ahmed M. Musa, University of Khartoum (Sudan) (TBC)

- Helminths: Partnering for the pipeline
  Coralie Martin, Muséum National d’Histoire Naturelle (France)

- Nothing less than health for all – what is at stake when we talk about partnership and innovation for NTDs
  Spring Gombe, Market Access Africa (Switzerland)

3.1 Workshop

08:00-09:00
Room 342A

More Informative Clinical Trials: The DAC-A Story

Organiser: Global Health Strategies (United States)

3.1 Plenary session V

09:05-10:15
Amphitheatre Bordeaux

Chair: Catherine Hankins (Canada)

Debate: Inequalities in Global Health

Moderator: Catherine Hankins, McGill University (Canada)

Speakers:
- Nkando Luo, Global One Health Institute, Lusaka Environmental Health University (Zambia) (TBC)
- Margaret Gyapong, University of Health and Allied Sciences (UHAS, Ghana)
- Magda Robalo Correia Silva, Institute for Global Health and Development (Guinea-Bissau)
- Francisco Saúte, Director General of the Manhiça Health Research Centre (CISM, Mozambique)

Break

10:15-10:45

3.1 Parallel session

10:45-12:30
Room 341

Partnerships

Chairs: Lara Pandya (The Netherlands) and Richard Adegbola (Nigeria)

OA-059 Achieving equitable leadership in Global Health partnerships: barriers experienced and strategies to improve grant funding for early and mid-career researchers in low- and middle-income countries
Toyon Togun, London School of Hygiene and Tropical Medicine (LSHTM, United Kingdom)

OA-217 Introducing a priority review voucher in the EU to encourage neglected disease product development
Agustin Martin Lasanta, Deutsche Stiftung Weltbevoelkerung (DSW, Belgium)

OA-358 Innovative access approach to translate R&D into impact for preschool-aged children suffering from schistosomiasis
Beatrice Greco, ARES Trading SA, an affiliate of Merck KGaA, Darmstadt (Germany) - on behalf of Pediatric Praziquantel Consortium

OA-533 UKCDR: enhancing coherence, collaboration, and joint action in the UK research funding landscape and beyond
Maggy Heintz, UK Collaborative on Development Research (UKCDR, United Kingdom)
| OA-902 | Empower African R&D stakeholders to advance equitable and sustained access to quality health products: toward policy recommendations  
Raffaella Ravinetto, Institute of Tropical Medicine (ITM, Belgium) |

### 3.2 Parallel session |

**Maternal and child health**

Chairs: Montserrat Blazquez-Domingo (The Netherlands) and Andiswa Zitho (South Africa)

| OA-058 | Associations between prenatal malaria exposure, maternal antibodies at birth and malaria susceptibility during the first year of life in Burkina Faso  
Hamtandi Magloire Natama, Institut de Recherche en Sciences de la Sante - Unité de Recherche Clinique de Nanoro (Burkina Faso) |
| OA-099 | Evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women: a multi-centre, double-blind, placebo-controlled trial (MAMAH project)  
Raquel González, Barcelona Institute for Global Health (Spain) |
| OA-183 | Dynamic of molecular and resistance markers prevalence of *Plasmodium falciparum* during the seasonal malaria chemoprevention campaign in school aged children in Bandiagara, Mali  
Karim Traoré, Malaria Research and Training Center, Université des Sciences, des Techniques et des Technologies de Bamako (USTTB, Mali) [Video presentation] |
| OA-218 | Enhanced effect of seasonal malaria chemoprevention when coupled with nutrients supplementation for preventing malaria in children under five years old in Burkina Faso  
Paul Sondo, Institut de Recherche en Sciences de la Santé/Clinical Resaerch Unit of Nanoro (Burkina Faso) |
| OA-429 | High mortality in African infants living with HIV hospitalized with severe pneumonia  
Bwendo Nduna, Arthur Davison Children's Hospital (Zambia) |
| OA-715 | Receipt of intravenous co-amoxiclav challenges eligibility screening for the PediCAP Trial in Johannesburg, South Africa  
David Moore, University of the Witwatersrand (South Africa) |

### 3.3 Parallel session |

**Capacity strengthening**

Chairs: Michelle Nderu (South Africa) and Debora Bade (The Netherlands)

| OA-189 | Building capacity for HIV cure research in Ghana - The H-CRIS Experience  
George Kyei, University of Ghana (Ghana) |
| OA-098 | Creating a whole that is more than the sum of its parts: an emerging collaboration between clinical trial units in UK, West and East Africa  
Armel Zemsi, Medical Research Unit The Gambia at the London School of Hygiene & Tropical Medicine (The Gambia) [Video presentation] |
| OA-900 | A bilingual training platform in data management and sharing to support open science across the EDCTP Networks of Excellence  
Aboubakar Soma, Centre MURAZ, National Institute of Public Health (Burkina Faso) |
| OA-903 | Breaking Barriers, Bridging Knowledge: Inclusion of Women in clinical research by Addressing Gender and Diversity Regional Gaps in Clinical Research Capacity in Africa  
Mwansa Ketty Lubeya, University Teaching Hospitals, The University of Zambia (Zambia) |
| OA-904 | Role of Pathogen Genomics in Public Health: Lessons from HIV and COVID-19 towards pandemic preparedness  
Sikhulile Moyo, Botswana Harvard AIDS Institute Partnership (Botswana) |

**Networking lunch**  
12:30-14:00

**Meet the experts III**  
12:30-13:30

**Poster presentations - C**  
12:45-14:00
<table>
<thead>
<tr>
<th>Plenary session VI</th>
<th>14:00-15:40 AmphiTheatre Bordeaux</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Panel: Global Health EDCTP3: strategy and links with other global initiatives</strong></td>
<td>14:00-15:00</td>
</tr>
<tr>
<td>Moderator: Pauline Beattie (The Netherlands) and Thomas Nyirenda (South Africa)</td>
<td></td>
</tr>
<tr>
<td><strong>Speakers:</strong></td>
<td></td>
</tr>
<tr>
<td>• John Gyapong, Adjunct Professor of Global Health, Georgetown University, USA; Chairperson of the Scientific Committee of the Global Health EDCTP3 Joint Undertaking (Ghana)</td>
<td></td>
</tr>
<tr>
<td>• Nevena Miletic, Policy Head EMEA, Global Regulatory Policy at F. Hoffmann-La Roche and Co-Chair of IFPMA’s African Regulatory Network (Switzerland)</td>
<td></td>
</tr>
<tr>
<td>• Lindiwe Makubalo, Assistant Regional Director, World Health Organisation Africa Regional Office</td>
<td></td>
</tr>
<tr>
<td>• Jean Kaseya, Director General, Africa Centres for Disease Control and Prevention (Africa CDC)</td>
<td></td>
</tr>
<tr>
<td><strong>Closing ceremony</strong></td>
<td>15:00-15:40</td>
</tr>
<tr>
<td>Harleen Grewal, Forum Scientific Programme Committee Chair and EDCTP Scientific Advisory Committee Chair (Norway)</td>
<td></td>
</tr>
<tr>
<td>Michael Makanga, EDCTP Association (The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Tunji Alausa, Minister of State, Health and Social Welfare (Nigeria)</td>
<td></td>
</tr>
<tr>
<td>Anne-Claire Ampiou, the French Ambassador for Global Health</td>
<td></td>
</tr>
</tbody>
</table>